Top 4 Opening Gainers: A123 Systems, Pluristem Therapeutics, Merrimack (AONE, PSTI, STEM, MACK)

U.S. stocks gaped down this morning after recent rally on Friday. However, there are several stocks which are showing solid gains:-

A123 Systems, Inc.(NASDAQ:AONE) shares are showing solid recovery in the opening session on Friday with a gain of 21.40% to $0.839 on hefty volume after the company reached with China's Ray Power Systems to supply a 2MW grid energy storage system. Though 2MW may not sound like much, Ray Power proclaims the deal will "validate the technical capabilities" of grid storage, and A123 is hopeful it will open up new opportunities in China. Selling energy tech in the country has its risks, as American Superconductor and Maxwell can vouch.

Can AONE Bounce back above $1 Mark? Find Free Trend Analysis

Pluristem Therapeutics Inc.(NASDAQ:PSTI) extended its prior session’s gain and rose 15.62% to $3.70 after creating a new 52-week high of $3.85. Yesterday, the stock ended higher by 19% after the Israeli biotech company announced that CPC Clinical Research will be managing the company's upcoming Phase II clinical trial for its proprietary stem-cell therapy in the treatment of peripheral artery disease. Pluristem said that CPC is a specialist in conducting clinical trials for the condition.

How Should Investors Trade PSTI after Recent Rally, Get Trend Analysis

Merrimack Pharmaceuticals Inc(NASDAQ:MACK) added 9% to $7.89 and made a new 52-week high of $9.20 earlier in the session. Earlier this week, the company announced the election of James Quigley, CEO emeritus of Deloitte Touche Tohmatsu, Limited (the Deloitte Global Network), to its Board of Directors. Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer.

Get Trend Analysis on MACK

StemCells, Inc.(NASDAQ:STEM) added 13% to $1.58. Earlier this week, the company announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease (AD). The data was presented today at the Alzheimer's Association International Conference 2012 in Vancouver, Canada.